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cohort with peripheral arterial disease
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Background:This study analyzed risk factors for mortality in peripheral arterial disease (PAD), including bodymass index
(BMI) and estimated glomerular filtration rate (eGFR). Risk factors for long-term survival are unclear in patients with
PAD. The origin of the obesity paradox, a paradoxical decrease inmortality with increasing BMI, is also uncertain in these
patients.
Methods: A prospective cohort study was performed in 652 patients (aged 71.3  9.4 years old) with PAD.
Results: The 1-, 5-, 10- and 15-year survival rates were 94.5%, 70.4%, 45.2%, and 21.1%, respectively, in patients with
intermittent claudication, and 72.7%, 27.2%, 11.6%, and 5.8%, respectively, in those with critical limb ischemia (CLI). In
Cox multivariate analysis, a significant association with all-cause mortality was found for CLI (hazard ratio [HR], 1.931;
95% confidence interval [CI], 1.089-3.422; P .024), diabetes (HR, 2.111; 95% CI, 1.247-3.572; P .005), BMI (HR,
0.879; 95%CI, 0.804-0.962; P .005), and eGFR (HR, 0.985; 95%CI, 0.971-0.998l; P .028). These parameters were
also significant risk factors for cardiovascular mortality. Fibrinogen (HR, 1.003; 95% CI, 1.001-1.005; P  .014) and
cerebrovascular disease (HR, 1.730; 95% CI, 1.021-2.930; P  .045) were identified as risk factors for all-cause
mortality. The adjusted HR for mortality of BMI <21.5 vs >21.5 kg/m2 was 1.772 (95% CI, 1.378-2.279; P < .001).
BMI had positive correlations with triglyceride and albumin concentrations and negative correlations with the fibrinogen
level and chronic obstructive pulmonary disease (P  .005).
Conclusions: Low BMI, eGFR, CLI, and diabetes are significant risk factors for mortality in PAD. The obesity paradox
was verified and may be partly explained by low BMI mediated by malnutrition and systemic inflammation due to PAD
or chronic obstructive pulmonary disease. ( J Vasc Surg 2010;52:110-7.)Peripheral arterial disease (PAD) is characterized by
multiple atherosclerosis risk factors and a high incidence of
coexisting atherosclerotic vascular disease.1 Cardiovascular
disease (CVD) is the predominant cause of late mortality in
patients with PAD,1-3 and the increased risk of cardiovas-
cular events in PAD is related to the severity of the disease
in the legs.2-4 Patients with critical limb ischemia (CLI)
have 20% mortality in the first year after presentation, and
long-term survival in CLI is unclear.1 Chronic kidney dis-
ease (CKD) also appears to be a risk factor for CVD,4-6 and
patients with PAD frequently also have CKD.6-8 This is
important because patients with CKD are more likely to die
of CVD than to develop kidney failure.9 Recent studies of
the estimated glomerular filtration rate (eGFR) have found
From the Departments of Vascular Medicinea and Cardiovascular Surgery,b
Cardiovascular Hospital of Central Japan (Kitakanto Cardiovascular Hos-
pital).
Competition of interest: none.
Reprint requests: Hisao Kumakura,MD,Department of VascularMedicine,
Cardiovascular Hospital of Central Japan (Kitakanto Cardiovascular Hos-
pital), Shimohakoda 740,Hokkitu-machi Shibukawa-city, Gunma Prefec-
ture, 377-0061, Japan (e-mail: kumakura@sannet.ne.jp).
The editors and reviewers of this article have no relevant financial relationships
to disclose per the JVS policy that requires reviewers to decline review of any
manuscript for which they may have a competition of interest.
0741-5214/$36.00
Copyright © 2010 by the Society for Vascular Surgery.
doi:10.1016/j.jvs.2010.02.008
110that this parameter is a better predictor of death than serum
creatinine alone in patients with PAD or CVD.5-7
Obesity is also an established risk factor for increased
cardiovascular death.10-14 However, in patients with a
known CVD, a paradoxical decrease in death with increas-
ing body mass index (BMI, calculated as kg/m2) has been
found; this is referred to as the “obesity paradox.”15-18 In
patients with PAD, mortality also decreases with increasing
BMI, and chronic obstructive pulmonary disease (COPD)
partly explains the obesity paradox.19However, smoking or
lung diseases such as COPD do not completely explain this
paradox in a subgroup of overweight or obese patients who
have better survival,20 and several mechanisms have been
proposed to account for the paradox in CVD.15-18,20 The
purpose of this study was to examine long-term survival in
patients with PAD with reference to severity of symptoms,
CKD, and BMI, including the obesity paradox. We also
examined other clinical and laboratory parameters as poten-
tial predictors of death in patients with PAD.
METHODS
The study protocol was approved by the Cardiovascular
Hospital of Central Japan (Kitakanto Cardiovascular Hos-
pital) Medical Ethical Committee (CCJ-EA-006).
Patients. The participants were 709 patients whowere
referred to the Cardiovascular Hospital of Central Japan
(Kitakanto Cardiovascular Hospital) between January 1,
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brachial pressure index (ABI) 0.90 at their first visit. The
final diagnosis of PAD was based on clinical symptoms and
iliac or femoropopliteal artery stenosis of70% on angiog-
raphy or ultrasound imaging.
Participants were provided with a full explanation of the
treatment and the study and gave informed consent to
register with the Foot Care Club in our hospital. Through
this club, we organized educational meetings to provide
lectures on foot care and new medical trends, and an
invitation to the meeting and a questionnaire was sent to
each patient once a year.
The study end point was all-cause and cardiovascular
death. Information on vital status was assessed using hos-
pital records and written questionnaires completed at the
meeting or in response to the invitation letter. If the
patients did not provide answers to the questionnaire, a
telephone interview of the patient or his or her family was
performed. The cause of death was determined from the
death certificate. For patients who died in another hospital
or at home, we defined the cause of death from the death
certificate issued by the hospital or clinic, with the agree-
ment of their families. Patients with an unknown cause of
death were excluded from the analysis.
Clinical and laboratory analysis. Clinical data were
obtained by a thorough review of primary data, including
age, height, weight, ABI, smoking history, diabetes melli-
tus (DM), and hypertension. An electrocardiogram was
recorded, and echocardiography and a brain computed
tomography scan were performed for each patient.
Coronary heart disease (CHD) was considered to be
present if the patient had a history of this disease or showed
a positive sign in stress/rest myocardial perfusion scintig-
raphy or coronary angiography. Cerebrovascular disease
(CBVD) was considered positive if the patient had a history
of this condition or if lesions due to cerebral infarction were
found in a brain computed tomography scan. COPD was
defined as positive based on medical history or a forced
expiratory volume % (forced expiratory volume in 1 sec-
ond/forced vital capacity) 70%.21
Blood was collected during fasting to determine total
protein, albumin, creatinine, total cholesterol, high-density
lipoprotein cholesterol (HDL-C), triglyceride, lipopro-
tein(a), remnant-like particle cholesterol,22 glucose, glyco-
sylated hemoglobin A1c, fibrinogen, D-dimer, and homo-
cysteine. Lipid abnormalities were diagnosed based on total
cholesterol 219 mg/dL or intake of lipid-lowering
agents,23 HDL-C 40 mg/dL,1 and triglyceride 150
mg/dL.24
The glomerular filtration rate was estimated using the
Modification of Diet in Renal Disease Study equation for
creatinine, as modified by the Japanese Society of Nephrol-
ogy: eGFR (mL/min/1.73 m2)  194  (serum creati-
nine)–1.094  (age)–0.287 ( 0.739 if female).25 CKD was
divided into five stages according to The National Kidney
Foundation–Kidney Disease Outcomes Quality Initiative
(NKF-K/DOQl) guidelines.26 Patients were grouped ac-
cording to the BMI classifications of the National Institutesof Health as underweight (18.5 kg/m2), normal weight
(18.5-24.9 kg/m2), overweight (25-29.9 kg/m2), or
obese (30 kg/m2).27
Drug administration and treatment. All patients re-
ceived one or more antiplatelet agents. Administration of
oral drugs for treatment of PAD (cilostazol, beraprost, or
sarpogrelate) was continued, and oral aspirin, ticlopidine,
or clopidogrel was added as an antiplatelet agent for endo-
vascular treatment and bypass surgery. Patients who expe-
rienced adverse effects such as bleeding, appetite loss, head-
ache, or palpitation, were treated with only one agent.
Drugs for hypertension and hyperlipidemia that were used
before treatment were also administered continuously, and
drugs for other medical treatments were added according
to need. Oral drugs administered for 3 months or those
administered 3 months before death were classified as
medical treatment.
We explained the effects of the medical treatment and
continued to make efforts to ensure that the patients con-
tinued with the prescribed medicine during visits to the
outpatient department or at foot care lectures. Patients
were classified into three groups based on treatment: med-
ical treatment, endovascular treatment, and bypass surgery.
Those who received two or more kinds of treatment were
included in the most invasive treatment group.
Statistical analysis. Results for continuous data are
expressed as averages  standard deviation. Analysis of
variance was used for comparison of continuous variables
with Bonferroni adjustment for the multiplicity of individ-
ual pairs. The Kaplan-Meier method was used to determine
survival in the follow-up period, and a log-rank test was
performed for comparisons. The hazard ratio (HR) and
confidence interval (CI) were calculated for individual fac-
tors in a Cox univariate analysis. Factors with P .05 in this
analysis were used in amultivariate Cox regressionmodel to
determine predictors of the end point. The Pearson corre-
lation coefficient was used for evaluating simple correla-
tions between BMI and other metabolic parameters. Step-
wise forward multiple regression analysis was used for
studying multiple regression models for BMI and signifi-
cant parameters. Cardiovascular and noncardiovascular
mortality was compared using a 2 test. Individual differ-
ences were considered to be statistically significant for P 
.05. SPSS 16.0 software (SPSS Inc, Chicago, Ill) was used
for all calculations.
RESULTS
Patient characteristics. Follow-up was possible for
652 of the 709 participants. Their mean age was 71.3 9.4
years (range, 38-97 years). The median follow-up period
was 5.4 years (range, 1 month-16.8 years). Intermittent
claudication was observed in 501 patients and CLI in 151.
Baseline characteristics and comorbidities are reported in
Table I.
Cause of death and survival rates. There were 298
deaths during follow-up. Causes of death were cardiac or
major vascular disease in 103 (34.6%), CBVD in 53
(17.8%), malignancy in 56 (18.8%), pneumonia in 40
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(11.4%). Among the deaths due to cardiac or major vascu-
lar disease, 61 patients (20.4%) died of acute myocardial
infarction, and 33 (11.1%) died of heart failure. Among the
deaths due to malignancy, 19 (6.4%) died of gastrointesti-
nal carcinoma, and 15 (5.0%) died of lung cancer. The
estimated all-cause mortalities for the age-matched (71-
year-old) general population based on the abridged life
tables of the 2008 Health of the Nation report were malig-
nancy, 42.9%; cardiac disease, 13.7%; CBVD, 11.0%; pneu-
monia, 6.4%; and accident, 3.5%.28 Therefore, cardiovas-
cular deaths in patients with PADwere higher than those in
the age-matched population.
The cumulative survival rates in all patients at 1, 5, 10,
and 15 years were 89.6%, 61.6%, 37.4%, and 17.4%, respec-
tively, and were 94.5%, 70.4%, 45.2%, and 21.1%, respec-
Table I. Baseline clinical characteristics in 652 patients
with peripheral arterial disease
Variable Avg  SD or No. (%)
Age, y 71.3  9.4
Male gender 512 (78.5)
Intermittent claudication 501 (76.8)
Critical limb ischemia 151 (23.2)
Ankle-brachial index 0.61  0.26
Body mass index, kg/m2 21.95  4.01
Risk factors
Hypertension 377 (57.8)
Diabetes mellitus 202 (31.0)
Dyslipidemia 210 (32.2)
Coronary heart disease 249 (38.2)
Cerebrovascular disease 124 (19.0)
eGFR, mL/min/1.73 m2 52.5  21.0
Hemodialysis 39 (6.0)
Smoking history 459 (70.4)
COPD 115 (17.6)
Dyslipidemia 210 (32.2)
Hypercholesterolemia 94 (14.4)
Low HDL cholesterol 172 (26.4)
High triglyceride 155 (23.8)
Other drugs
Aspirin 297 (45.5)
Ticlopidine 129 (19.8)
Clopidogrel 69 (10.6)
Cilostazol 270 (41.4)
Beraprost 263 (40.3)
Sarpogrelate 51 (7.8)
Eicosapentaenoic acid 69 (10.6)
Warfarin 83 (12.7)
ACE inhibitor 101 (14.0)
Angiotensin receptor blocker 123 (18.9)
Calcium antagonist 289 (44.3)
-blocker 73 (11.2)
Statin 140 (21.5)
Treatment
Medical treatment 206 (31.6)
Endovascular treatment 293 (44.9)
Bypass surgery 153 (23.5)
Amputation 32 (4.9)
ACE, Angiotensin-converting enzyme; COPD, chronic obstructive pulmo-
nary disease; eGFR, estimated glomerular filtration rate; SD, standard devi-
ation.tively, in patients with intermittent claudication and 72.7%,27.2%, 11.6%, and 5.8%, respectively, in those with CLI
(Fig 1). The estimated all-cause survival of the 71-year-old
population in the abridged life tables of the 2008 Health of
the Nation report is also shown in Fig 1.28 The average
mortality of PAD patients was 1.9 times higher in those
with intermittent claudication and 4.8 times higher in those
with CLI compared with the age-matched general popula-
tion.
Cox univariate and multivariate analysis. The re-
sults of Cox univariate analysis of potential risk factors and
the HRs for all-cause and cardiovascular mortality are re-
ported in Table II. Age, CLI, ABI, BMI, DM, eGFR,
CBVD, CHD, D-dimer, albumin, and fibrinogen were
significant factors associated with all-cause mortality in the
follow-up period. Medical treatment with aspirin, statins,
angiotensin-converting enzyme inhibitors/angiotensin re-
ceptor blockers, and calcium antagonists was associated
with improved survival in univariate analysis. Endovascular
treatment or bypass surgery was significantly associated
with improved survival compared withmedical treatment in
Cox univariate and Kaplan-Meier survival analyses. The
mean ages in the medical treatment, endovascular treat-
ment, and bypass surgery groups were 74.4  9.8, 70.4 
9.1, and 68.8  8.3 years, respectively, with a significant
difference in mean age between the medical treatment
group and the other two groups (P  .001).
A Cox multivariate analysis found age, CLI, BMI, DM,
and eGFR were significant factors for all-cause and cardio-
vascular deaths. CBVD and fibrinogen were also significant
factors associated with all-cause mortality, and CHD
showed a tendency to be associated with both all-cause and
cardiovascular deaths.
Renal function and mortality. As determined by
eGFR (mL/min/1.73 m2), only 21 patients (3.2%) had
normal kidney function (eGFR 90), 175 (26.8%) had
mildly impaired kidney function (eGFR, 60-89), 387
(59.4%) had moderate renal insufficiency (eGFR, 30-59),
26 (4.0%) had severe renal insufficiency (eGFR, 15-29),
and 43 (6.6%) had renal failure (eGFR 15), including 39
(6.2%) who were receiving hemodialysis.
All-cause survival is presented as a Kaplan-Meier curve
in Fig 2. All-cause survival was lower in patients with
eGFR 30 mL/min/1.73 m2 (P  .001) and higher in
those with eGFR 60 mL/min/1.73 m2 (P  .05) com-
pared with patients with moderate renal insufficiency
(eGFR 30-59 mL/min/1.73 m2). Mortality was signifi-
cantly higher for patients with eGFR 30 vs eGFR 30
mL/min/1.73 m2 (adjusted HR, 2.73; 95% CI, 1.914-
3.900; P  .001).
BMI and mortality. The distribution of BMI in the
population was approximately normal, with a mean of 22.0 
4.1 kg/m2. Only 11 patients (1.7%) with PAD were obese,
102 (15.6%) were overweight, 439 (67.3%) were normal
weight, and 100 (15.3%) were underweight. All-cause sur-
vival is shown as a Kaplan-Meier curve in Fig 3. All-cause
survival was lower in underweight patients (P  .001) and
higher in overweight or obese patients (P .05) compared
with patients of normal weight (BMI, 18.5-24.9 kg/m2).
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higher in underweight patients and lower in normal or
mildly overweight patients (Fig 4). The curve was J-shaped,
and cardiovascular mortality showed a tendency for a bi-
modal distribution, with two peaks in the lower and higher
BMI strata.
Calculation of the cutoff level of the adjusted mortality
OR for each level of BMI showed that the HR for mortality
was greatest for patients with BMI 21.5 vs BMI 21.5
kg/m2 (adjusted HR, 1.772; 95% CI, 1.378-2.279; P 
.001). The mean BMIs in cases of cardiovascular and
noncardiovascular death were 21.4  3.0 and 21.0  3.4
kg/m2, and the mean BMI of patients who died of malig-
nancy was 21.0  3.0 kg/m2, with no significant differ-
ences among these values. However, noncardiovascular
death (mostly due tomalignancy or pneumonia) was higher
in patients with BMI 18.5 kg/m2 than in patients with
BMI 18.5 kg/m2 (P  .040).
BMI was positively correlated with ABI, total choles-
terol, triglyceride, remnant-like particle cholesterol, total
protein, albumin, hypertension, and DM, and was nega-
tively correlated with age, CLI, lipoprotein (a), fibrinogen,
D-dimer, and COPD (P .05). Stepwise forward multiple
regression analysis of the relationship between BMI and
these factors revealed a significant positive correlation with
triglyceride and albumin and a significant negative correla-
tion with fibrinogen and COPD (Table III, P  .005).
DISCUSSION
CVD is a major cause of death, accounting for 52.3% of
deaths in patients with PAD. The risk of death was about
1.9 times higher in PAD patients with intermittent claudi-
cation and 4.8 times higher in CLI than in the age-matched
Fig 1. Cumulative all-cause survival rates are shown for
ischemia (CLI) (**P  .001, IC vs CLI). The estimate
population (GP) is also shown.general population.28 In the TransAtlantic Inter-SocietyConsensus (TASC) II report,1 patients with chronic CLI
had a 20% mortality rate in the first year after presentation,
and the little long-term data available suggest that mortality
continues at the same rate.1 Our results approximately
match the TASC-II findings. Mortality has strong correla-
tions with CLI and ABI as a measure of the severity of PAD,
and DM also increases the risks of PAD and cardiovascular
death.1,3,4 In patients with type 2 DM, a lower ABI is
related to a higher 5-year risk of a cardiovascular event.29
These consistent results suggest that severe PAD with the
complication of DM involves extensive and severe degrees
of systemic atherosclerosis that is responsible for the mor-
tality caused by CVD.
Our study found eGFR was an independent predictor
of mortality in PAD. Several studies have suggested that
CKD is a prognostic indicator of CVD,5,30 and an associa-
tion between survival and eGFR or estimated creatinine
clearance in patients with PAD has recently been pro-
posed.6-8 Maithet et al6 showed that estimated creatinine
clearance, but not the serum creatinine level, predicted
3-year survival after lower limb bypass surgery indepen-
dently of dialysis. O’Hare et al8 found that CKD was a
strong independent predictor of death in CLI patients and
that the mortality risk was highest among patients with an
eGFR 30 mL/min/1.73 m2. The eGFR has also been
shown to be an independent predictor of death and limb
loss after infrainguinal bypass, with only 45.7% of CLI
patients with eGFR30 mL/min/1.73 m2 surviving after
1 year.7 In our study, patients with eGFR 30 vs eGFR
30 mL/min/1.73 m2 had adjusted HR for mortality of
2.73. CKD also appeared to be a risk factor for patients with
PAD, which suggests that treatment for maintenance of
nts with intermittent claudication (IC) and critical limb
cause survival of an age-matched (71-year-old) generalpatie
d all-renal function is important in patients with a low eGFR.
, endo
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CVD15-18 and PAD.16,19,20 COPD is identified as a cardiac
risk factor31 that preferentially affects underweight individuals
and partly explains the obesity paradox in PAD patients.19
However, adjusting for the severity ofCOPDdoes not abolish
the relationship between BMI and mortality in overweight
and obese patients.16,20,31 In our patients, the 5-year mortal-
ity rates for different levels of BMI followed a J-shaped curve.
Cardiovascular mortality showed a tendency for a bimodal
distribution, with two peaks in the lower and higher BMI
strata. BMI also had significant positive correlations with
triglyceride and albumin and significant negative correlations
with fibrinogen and COPD.
Several mechanisms may explain the obesity paradox in
Table II. Cox univariate and multivariate analysis of poten
Variable
All-cause mortality
Univariate analysis Multivariate anal
HR (95% CI)
P
value HR (95% CI)
Age, year 1.066 (1.051-1.082) .001 1.074 (1.037-1.11
Male gender 0.907 (0.665-1.238) .538 . . .
CLI vs IC 3.337 (2.589-4.302) .001 1.931 (1.089-3.42
ABI 0.362 (0.232-0.564) .001 0.561 (0.220-1.43
BMI 0.866 (0.831-0.902) .001 0.879 (0.804-0.96
Risk factors
Diabetes 1.750 (1.220-2.511) .002 2.111 (1.247-3.57
eGFR 0.979 (0.972-0.986) .001 0.985 (0.971-0.99
CBVD 1.648 (1.256-2.162) .001 1.730 (1.021-2.93
CHD 1.492 (1.002-2.222) .049 1.903 (0.982-3.68
Hypertension 0.946 (0.745-1.196) .648 —
Dyslipidemia 1.002 (0.996-1.009) .470 —
Smoking 1.139 (0.873-1.139) .338 —
COPD 1.116 (0.867-1.435) .394 —
Laboratory data
Albumin 0.378 (0.266-0.538) .001 0.761 (0.543-1.63
Fibrinogen 1.002 (1.001-1.004) .001 1.003 (1.001-1.00
D-dimer 1.108 (1.066-1.153) .001 1.014 (0.926-1.11
RLP-C 0.971 (0.930-1.013) .171 —
Medication
Aspirin 0.623 (0.481-0.807) .001 0.707 (0.430-1.16
Ticlopidine 0.928 (0.742-1.312) .928 —
Clopidogrel 1.115 (0.727-1.709) .618 —
Cilostazol 1.165 (0.921-1.473) .253 —
Beraprost 0.997 (0.777-1.278) .979 —
Sarpogrelate 1.047 (0.632-1.735) .859 —
Warfarin 1.017 (0.735-1.407) .920 —
EPA 1.326 (0.966-1.818) .080 —
ACE or ARB 0.665 (0.496-0.891) .006 0.759 (0.435-1.32
Calcium
antagonist 0.779 (0.617-0.982) .034 0.774 (0.493-1.21
-blocker 0.769 (0.524-1.130) .181 —
Statin 0.488 (0.328-0.726) .001 0.657 (0.303-1.42
Treatment vs
medical
treatment
EVT 0.525 (0.402-0.686) .001 0.663 (0.365-1.20
Bypass 0.666 (0.489-0.907) .010 1.182 (0.638-2.18
ABI, Ankle brachial pressure index; ACE, angiotensin-converting enzyme
cerebrovascular disease; CHD, coronary heart disease; CI, confidence inte
eGFR, estimated glomerular filtration rate; EPA, eicosapentaenoic acid; EVT
remnant-like particle cholesterol.patients with CVD.15-18,20 Davenport et al17 reported thata low serum albumin concentration was a risk factor for
poor outcome, in addition to CLI and CAD, after various
vascular surgeries. Furthermore, malnutrition and inflam-
mation are recognized as important risk factors for CVD in
hemodialysis patients.32 Another potential explanation is
the presence of cardiac cahexia.33 Studies have demon-
strated that many patients with advanced heart failure are
malnourished, with a calorie and protein intake that is
inadequate to meet their energy requirements.33,34 Komai
et al35 reported that plasma adiponectin was negatively
correlated with BMI, and high adiponectin levels were
associated with an increased risk of death after peripheral
vascular surgeries.
Fibrinogen and D-dimer are markers of activated coagula-
risk factors for all-cause and cardiovascular mortality
Cardiovascular
mortality
Univariate analysis Multivariate analysis
P
alue HR (95% CI)
P
value HR (95% CI)
P
value
.001 1.049 (1.029-1.071) .001 1.039 (1.006-1.073) .022
0.721 (0.478-1.086 .117
.024 2.885 (1.996-4.169) .001 1.970 (1.124-3.454) .018
.226 0.425 (0.224-0.804) .009 0.518 (0.196-1.370) .185
.005 0.875 (0.826-0.927) .001 0.885 (0.812-0.964) .005
.005 1.550 (1.045-2.300) .029 2.457 (1.172-5.150) .017
.028 0.977 (0.968-0.987) .001 0.984 (0.970-0.999) .033
.045 1.529 (1.030-2.270) .035 1.221 (0.689-2.165) .494
.056 1.519 (1.016-2.246) .042 1.577 (0.942-2.641) .083
1.183 (0.843-1.659 .331 — —
0.906 (0.602-1.362 .452 — —
1.301 (0.902-1.877 .159 — —
1.132 (0.871-1.484 .341 — —
.834 0.359 (0.222-0.581) .001 0.898 (0.437-1.847) .770
.014 1.003 (1.002-1.005) .001 1.000 (0.997-1.004) .254
.770 1.128 (1.075-1.184) .001 1.033 (0.928-1.151) .548
— 0.964 (0.897-1.036 .314 — —
.173 0.638 (0.443-0.920) .016 0.667 (0.392-1.136) .136
— 0.894 (0.588-1.360 .600 — —
— 1.115 (0.727-1.709 .618 — —
— 1.150 (0.905-1.462 .323 — —
— 0.927 (0.649-1.324 .678 — —
— 0.642 (0.263-1.570 .332 — —
— 0.293 (0.845-1.981 .237 — —
— 1.277 (0.922-1.770 .142 — —
.331 0.763 (0.512-1.137) .184 — —
.266 0.908 (0.652-1.263) .565 — —
— 0.782 (0.532-1.150 .212 — —
.286 0.565 (0.331-0.966) .037 0.661 (0.274-1.597 0.357
.176 0.629 (0.425-0.931) .021 0.398 (0.156-1.010 0.052
.595 0.918 (0.595-1.416) .700 — —
itor; ARB, angiotensin receptor blocker; BMI, body mass index; CBVD,
LI, critical limb ischemia; COPD, chronic obstructive pulmonary disease;
vascular treatment;HR, hazard ratio; IC, intermittent claudication;RLP-C,tial
ysis
v
2) 
2)
2)
2)
2)
8)
0)
7)
7)
5)
0)
4)
4)
5)
2)
2)
8)
inhib
rval; Ction, fibrinolysis, and inflammation in PAD, and fibrinogen is
patien
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development of PAD.36 We also found an association between
fibrinogen and all-cause mortality. Thus, malnutrition, repre-
sentedby lowalbuminor triglyceride, andseverityof leg ischemia
or inflammation, indicated by a higher fibrinogen level, may be
causes of the increased risk in patients with lower BMI, in addi-
Fig 2. Cumulative all-cause survival rates are shown fo
(eGFR). Survival rates were lower in patients with eGFR
with eGFR 60 mL/min/1.73 m2 (*P  .05) than in
Fig 3. Cumulative all-cause survival rates are shown ba
patients with a BMI 18.5 kg/m2 (**P  .001) and h
patients with a BMI of 18.5 to 24.9 kg/m2.tion to the risk fromCOPD.There are conflicting data regarding whether obesity
itself confers an increased risk for CVD, apart from its
association with metabolic derangements.13,37 Further-
more, BMI is an imperfect metric for obesity or body fat
distribution18; waist circumference or the waist/hip ratio
are better indicators of a high risk for all-cause and cardio-
l function based on estimated glomerular filtration rate
mL/min/1.73 m2 (**P  .001) and higher in patients
ts with eGFR of 30 to 59 mL/min/1.73 m2.
n body mass index (BMI). Survival rates were lower in
in patients with a BMI 25 kg/m2 (*P  .05) than inr rena
30sed o
ighervascular mortality.37 Collectively, these factors suggest that
was 1
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July 2010116 Kumakura et althe obesity paradox might be a composite result of systemic
atherosclerosis mediated by malnutrition, systemic inflam-
mation, including severity of PAD or COPD, and the
multifactorial metric of BMI itself in patients with PAD.
The study also highlights the need to control nutri-
tional balance and systemic inflammation to reduce mortal-
ity. Nutrition management is especially important in pa-
tients with low BMI or low serum albumin and should be
performed in collaboration with a nutrition support team.
Control of inflammation is important with respect to
wound healing and management of COPD.
Our study has some limitations: First, the sample sizes
were relatively small and the study was performed at a single
facility. Second, the percentage of obese patients was small
and the mean age was high compared to studies in Western
countries,17,19 as in other Japanese studies.11,35 Third, data
for waist circumference and waist/hip ratio for measure-
ment of abdominal obesity were not routinely available.
Fig 4. The 5-year cardiovascular mortality (CVM) and
index (BMI). The curve is bimodal (J-shaped), and CVM
hazard risk of death for a BMI 21.5 vs 21.5 kg/m2
Table III. Correlation between body mass index and
other risk factors in stepwise forward multiple regression
analysisa
Risk factor  (95% CI)
P
value
Triglyceride, mg/dL 0.226 (0.004 to 0.012) .001
Albumin, mg/dL 0.152 (0.335 to 1.796) .004
Fibrinogen, mg/dL 0.151 (0.008 to 0.001) .004
COPD 0.152 (2.159 to 0.398) .005
CI, Confidence interval; COPD, chronic obstructive pulmonary disease.
aR2  0.148, F for change in R2  8.15, P  .005.Fourth, walking rehabilitation or physical fitness modu-lated the cardiovascular mortality,16 and the study did not
compensate for changes of BMI or lifestyle interventions
during follow-up. Therefore, further studies are needed to
reveal the precise mechanisms underlying the mortality.
CONCLUSIONS
Low BMI, CKD, CLI, and DM seem to be significant
risk factors for death in patients with PAD, and low eGFR is
an accurate predictor of death in PAD. BMI is another
independent predictor of death, and the obesity paradox
was verified in our study. Lower BMI mediated by malnu-
trition and systemic inflammation due to the severity of
PAD or COPD may partly explain the paradox. Therefore,
low BMI and eGFR should be used in addition to severity
of leg ischemia and control of DM in risk evaluation and
management of patients with PAD.
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